Jing Du, MD, PhD, MHS
Cards
About
Research
Publications
Featured Publications
Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer.
Jing Du, et al. J Clin Oncol 43, 1065(2025)Peer-Reviewed Original ResearchA Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-positive, HER2-negative Breast Cancer with a Combination Regimen of Ribociclib and Optimized Endocrine Therapy - SELECT Trial
Clin Cancer Res (2026) 32 (4_Supplement): PS5-09-06.Peer-Reviewed Original Research
2025
Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study
Korie U, Ai D, Podany P, Zhang H, Zhan H, Kahila M, Colon-Cartagena L, Wei S, Sun H, Du J, Krishnamurti U, Liang Y. Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study. American Journal Of Clinical Pathology 2025, 164: 704-711. PMID: 40994034, DOI: 10.1093/ajcp/aqaf088.Peer-Reviewed Original ResearchEpigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling.
Wang D, Di X, Gao F, Li G, Lin L, He S, Zhang D, Jin JY, Liang Y, Cecchini M, Lacy J, Kunstman J, Kunz P, Du J, Liu Y. Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC Profiling. BioRxiv 2025 PMID: 41000913, DOI: 10.1101/2025.09.11.675640.Peer-Reviewed Original Research
2022
Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Tyagi T, Jain K, Yarovinsky TO, Chiorazzi M, Du J, Castro C, Griffin J, Korde A, Martin KA, Takyar SS, Flavell RA, Patel AA, Hwa J. Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. Journal Of Experimental Medicine 2022, 220: e20212218. PMID: 36305874, PMCID: PMC9814191, DOI: 10.1084/jem.20212218.Peer-Reviewed Original ResearchUnfolded Protein Response Differentially Modulates the Platelet Phenotype
Jain K, Tyagi T, Du J, Hu X, Patell K, Martin KA, Hwa J. Unfolded Protein Response Differentially Modulates the Platelet Phenotype. Circulation Research 2022, 131: 290-307. PMID: 35862006, PMCID: PMC9357223, DOI: 10.1161/circresaha.121.320530.Peer-Reviewed Original Research
2020
Parkin Coordinates Platelet Stress Response in Diabetes Mellitus: A Big Role in a Small Cell
Lee SH, Du J, Hwa J, Kim WH. Parkin Coordinates Platelet Stress Response in Diabetes Mellitus: A Big Role in a Small Cell. International Journal Of Molecular Sciences 2020, 21: 5869. PMID: 32824240, PMCID: PMC7461561, DOI: 10.3390/ijms21165869.Peer-Reviewed Original Research14-3-3 ProteinsAnimalsBlood PlateletsCells, CulturedDiabetes MellitusHumansLysosomal Membrane ProteinsMiceMice, Inbred C57BLMitochondriaMitochondrial Trifunctional Protein, alpha SubunitMitophagyPlatelet ActivationProtein BindingProtein Serine-Threonine KinasesStress, PhysiologicalUbiquitin-Protein LigasesValosin Containing Protein
2019
Mitochondrial MsrB2 serves as a switch and transducer for mitophagy
Lee SH, Lee S, Du J, Jain K, Ding M, Kadado AJ, Atteya G, Jaji Z, Tyagi T, Kim W, Herzog RI, Patel A, Ionescu CN, Martin KA, Hwa J. Mitochondrial MsrB2 serves as a switch and transducer for mitophagy. EMBO Molecular Medicine 2019, 11: emmm201910409. PMID: 31282614, PMCID: PMC6685081, DOI: 10.15252/emmm.201910409.Peer-Reviewed Original ResearchAnimalsBlood PlateletsCell LineDiabetes MellitusFemaleHumansMethionine Sulfoxide ReductasesMice, Inbred C57BLMice, KnockoutMicrofilament ProteinsMicrotubule-Associated ProteinsMitochondriaMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMitophagyMutationOxidation-ReductionOxidative StressParkinson DiseaseSignal TransductionUbiquitin-Protein LigasesUbiquitinationAge associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
Jain K, Tyagi T, Patell K, Xie Y, Kadado AJ, Lee SH, Yarovinsky T, Du J, Hwang J, Martin KA, Testani J, Ionescu CN, Hwa J. Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. EBioMedicine 2019, 44: 28-40. PMID: 31130473, PMCID: PMC6604369, DOI: 10.1016/j.ebiom.2019.05.022.Peer-Reviewed Original ResearchAdaptation, PhysiologicalAge FactorsAgedAged, 80 and overAgingAnimalsAntioxidantsApoptosisBiomarkersBlood PlateletsCardiovascular DiseasesComorbidityDisease Models, AnimalFemaleHomeostasisHumansMaleMiceMiddle AgedOxidation-ReductionOxidative StressPlatelet ActivationPlatelet AdhesivenessReactive Oxygen SpeciesRisk AssessmentRisk Factors
2018
Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation
Wang D, Hu X, Lee SH, Chen F, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C, Liao Y, Shang H, Martin KA, Herzog RI, Young LH, Qian L, Hwa J, Xiang Y. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC Basic To Translational Science 2018, 3: 350-362. PMID: 30062222, PMCID: PMC6058960, DOI: 10.1016/j.jacbts.2018.01.005.Peer-Reviewed Original Research
Clinical Trials
Current Trials
An Open-label, Multi-center, Phase I/Ib Study of IEV407 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer
IRB ID2000042529RolePrincipal InvestigatorPrimary Completion Date06/08/2032Recruiting ParticipantsA Phase II Trial to Improve Safety of Capivasertib for HR+/HER2- Metastatic Breast Cancer
IRB ID2000037614RoleSub InvestigatorPrimary Completion Date04/01/2027Recruiting ParticipantsA Phase 1 Study of HLD-0117 in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC)
IRB ID2000042301RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsPalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
IRB ID2000041648RolePrincipal InvestigatorPrimary Completion Date12/01/2028Recruiting ParticipantsA Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
IRB ID2000041727RoleSub InvestigatorPrimary Completion Date05/31/2028Recruiting Participants
Clinical Care
Overview
Jing Du, MD, PhD, is a medical oncologist who specializes in the care of adults with breast cancer. She delivers compassionate, personalized care, tailoring treatments to meet each patient’s unique medical and personal needs.
As an assistant professor of medicine (medical oncology/hematology) at Yale School of Medicine, Dr. Du designs and leads clinical trials to investigate novel therapies with the goal of reducing treatment-related toxicities and improving patient outcomes. Her research interests focus on the tumor microenvironment and its role in cancer progression and treatment resistance. Utilizing cutting-edge techniques, she aims to identify new biomarkers to enhance cancer diagnosis and guide more effective, personalized treatment strategies.
Dr. Du received her medical degree from Shanghai Jiao Tong University School of Medicine and her doctoral degree in biochemistry from the University of South Carolina. Dr. Du pursued a Kirschstein-NRSA Training Fellowship at Yale School of Medicine and completed her residency and oncology-hematology fellowship at Yale New Haven Health.
Clinical Specialties
Fact Sheets
Breast Cancer
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale MedicineHormonal Therapy for Cancer
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.